Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S Azad

Showing results (151-160 of 199) with videos related to

Pageof 20
Sort By:
Oncotarget|April 29, 2017
Olaparib in combination with irinotecan, cisplatin, and mitomycin C in patients with advanced pancreatic cancerMark Yarchoan, Melinda C Myzak, Burles A Johnson, et al.
Clinical and Translational Science|August 2, 2020
A Phase I Study of Dinaciclib in Combination With MK-2206 in Patients With Advanced Pancreatic CancerAdrian G Murphy, Marianna Zahurak, Mirat Shah, et al.
Cancers|June 2, 2021
Clinical Predictors of Early Trial Discontinuation for Patients Participating in Phase I Clinical Trials in OncologyJoeri A J Douma, Laurien M Buffart, Ramy Sedhom, et al.
Clinical and Translational Science|April 3, 2021
A phase 2 trial of gemcitabine and docetaxel in patients with metastatic colorectal adenocarcinoma with methylated checkpoint with forkhead and ring finger domain promoter and/or microsatellite instability phenotypeMarina Baretti, Enusha Karunasena, Marianna Zahurak, et al.
Biorxiv : the Preprint Server for Biology|August 7, 2023
ME3BP-7 is a targeted cytotoxic agent that rapidly kills pancreatic cancer cells expressing high levels of monocarboxylate transporter MCT1Jordina Rincon-Torroella, Marco Dal Molin, Brian Mog, et al.
Journal of the American Chemical Society|August 11, 2023
Exciplex Emission and Förster Resonance Energy Transfer in Polycyclic Aromatic Hydrocarbon-Based Bischromophoric Cyclophanes and Homo[2]catenanesAmine Garci, Seifallah Abid, Arthur H G David, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 31, 2014
A Phase I study of veliparib (ABT-888) in combination with low-dose fractionated whole abdominal radiation therapy in patients with advanced solid malignancies and peritoneal carcinomatosisKim A Reiss, Joseph M Herman, Marianna Zahurak, et al.
Journal of the American Chemical Society|June 12, 2025
In Situ Encapsulation of Cationic [2]Catenane in a Stable Zirconium Metal-Organic FrameworkShuliang Yang, Isil Akpinar, Olga A Syzgantseva, et al.
Clinical Epigenetics|December 3, 2022
A randomized, phase II trial of oral azacitidine (CC-486) in patients with resected pancreatic adenocarcinoma at high risk for recurrenceThatcher R Heumann, Marina Baretti, Elizabeth A Sugar, et al.
Journal of the American Chemical Society|April 12, 2023
Divinylanthracene-Containing Tetracationic Organic Cyclophane with Near-Infrared PhotoluminescenceArthur H G David, Amine Garci, Seifallah Abid, et al.
Pageof 20

Showing results (151-160 of 199) with videos related to

Sort By:
Pageof 20
Oncotarget|April 29, 2017
Olaparib in combination with irinotecan, cisplatin, and mitomycin C in patients with advanced pancreatic cancerMark Yarchoan, Melinda C Myzak, Burles A Johnson, et al.
Clinical and Translational Science|August 2, 2020
A Phase I Study of Dinaciclib in Combination With MK-2206 in Patients With Advanced Pancreatic CancerAdrian G Murphy, Marianna Zahurak, Mirat Shah, et al.
Cancers|June 2, 2021
Clinical Predictors of Early Trial Discontinuation for Patients Participating in Phase I Clinical Trials in OncologyJoeri A J Douma, Laurien M Buffart, Ramy Sedhom, et al.
Clinical and Translational Science|April 3, 2021
A phase 2 trial of gemcitabine and docetaxel in patients with metastatic colorectal adenocarcinoma with methylated checkpoint with forkhead and ring finger domain promoter and/or microsatellite instability phenotypeMarina Baretti, Enusha Karunasena, Marianna Zahurak, et al.
Biorxiv : the Preprint Server for Biology|August 7, 2023
ME3BP-7 is a targeted cytotoxic agent that rapidly kills pancreatic cancer cells expressing high levels of monocarboxylate transporter MCT1Jordina Rincon-Torroella, Marco Dal Molin, Brian Mog, et al.
Journal of the American Chemical Society|August 11, 2023
Exciplex Emission and Förster Resonance Energy Transfer in Polycyclic Aromatic Hydrocarbon-Based Bischromophoric Cyclophanes and Homo[2]catenanesAmine Garci, Seifallah Abid, Arthur H G David, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 31, 2014
A Phase I study of veliparib (ABT-888) in combination with low-dose fractionated whole abdominal radiation therapy in patients with advanced solid malignancies and peritoneal carcinomatosisKim A Reiss, Joseph M Herman, Marianna Zahurak, et al.
Journal of the American Chemical Society|June 12, 2025
In Situ Encapsulation of Cationic [2]Catenane in a Stable Zirconium Metal-Organic FrameworkShuliang Yang, Isil Akpinar, Olga A Syzgantseva, et al.
Clinical Epigenetics|December 3, 2022
A randomized, phase II trial of oral azacitidine (CC-486) in patients with resected pancreatic adenocarcinoma at high risk for recurrenceThatcher R Heumann, Marina Baretti, Elizabeth A Sugar, et al.
Journal of the American Chemical Society|April 12, 2023
Divinylanthracene-Containing Tetracationic Organic Cyclophane with Near-Infrared PhotoluminescenceArthur H G David, Amine Garci, Seifallah Abid, et al.
Pageof 20